Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.58 |
| ▸ | TUBB | P07437 | 1/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.58 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.58 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.58 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.58 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.58 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.58 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.58 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.58 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.58 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.58 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5018042 | 0.81 | KMT2A (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5022812 | 0.78 | MAPT (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5016443 | 0.78 | MEN1 (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL570064 | 0.76 | TDP1 (0.57) | MAPTLMNAALDH1A1CTSVCTSL | |
| SCHEMBL656472 | 0.76 | HTT (0.60) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL29232880 | 0.75 | MAPT (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29232879 | 0.75 | MAPT (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4029762 | 0.74 | MAPT (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4029757 | 0.74 | MAPT (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4026837 | 0.74 | MAPT (0.45) | MAPTLMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182143-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-1620429-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS SA (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-7393846-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2008-07-01 | — | — | US | disclosed |
| US-7384962-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-06-10 | — | — | US | disclosed |
| US-7223789-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-29 | — | — | US | disclosed |
| US-20070105855-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-10 | — | — | US | disclosed |
| US-20070105854-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-10 | — | — | US | disclosed |
| US-20050027129-A1 | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS, INC. USA | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182143-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDE4A, PDE4B, PDE12 | TUBB4A 894/4885TUBB 2287/4885TUBA3C 2246/4885 |
| US-20050027129-A1 | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | PDE4A, PDE4B, PDE12 | TUBB4A 894/4885TUBB 2287/4885TUBA3C 2246/4885 |
| US-20070105854-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDE4A, PDE4B, PDE12 | TUBB4A 894/4885TUBB 2287/4885TUBA3C 2246/4885 |
| US-20070105855-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDE4A, PDE4B, PDE12 | TUBB4A 894/4885TUBB 2287/4885TUBA3C 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.